These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33884704)

  • 1. Predictive effect of antithyroid antibody for relapse of Graves' disease.
    Yoshizawa K; Aso K; Satoh M
    Pediatr Int; 2022 Jan; 64(1):e14749. PubMed ID: 33884704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
    Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
    Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
    Izumi Y; Takeoka K; Amino N
    Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
    Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
    Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.
    Choi YM; Kwak MK; Hong SM; Hong EG
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):268-274. PubMed ID: 31565879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of anti-thyroid drug treatment in childhood-onset Graves' disease.
    Puttawong D; Mahachoklertwattana P; Numthavaj P; Woratanarat P; Pongratanakul S; Koad P; Poomthavorn P
    Clin Endocrinol (Oxf); 2023 Jun; 98(6):823-831. PubMed ID: 36562146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months.
    Hwang S; Shin DY; Song MK; Lee EJ
    Endocrine; 2015 Feb; 48(1):89-95. PubMed ID: 24968734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review.
    Azizi F; Abdi H; Mehran L; Amouzegar A
    J Endocrinol Invest; 2022 Jun; 45(6):1139-1150. PubMed ID: 35088381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term follow up after antithyroid drug treatment in Graves' disease].
    Wille T; Müller B; Noth D; Bürgi U; Diem P
    Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE.
    Magri F; Zerbini F; Gaiti M; Capelli V; Ragni A; Rotondi M; Chiovato L
    Endocr Pract; 2016 Nov; 22(11):1336-1342. PubMed ID: 27540885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D; de Nayer P; Bex M;
    Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis.
    Shi H; Sheng R; Hu Y; Liu X; Jiang L; Wang Z; Cui D
    Clin Ther; 2020 Apr; 42(4):662-675.e4. PubMed ID: 32139177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
    Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
    Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
    Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
    J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.